The Painful Story Of Dry Eye Disease
Dry Eye might sound like something most can solve with OTC eye drops, but in reality 20% of the adult population worldwide report real quality of life impairment associated with this modern day epidemic. Dry Eye Disease is no small irritation, for millions of patients it’s a daily agony of light sensitivity, stabbing pain, gritty sand sensation, blurry vision, and in some cases can lead to severe vision impairment.
People in the US use pharmaceutical treatments,
usually with very low compliance or efficacy
Of ophthalmologists desire better treatment options
EpiTech’s technology – The promise of long-lasting, affordable relief
Viveye Ocular Magnetic Neurostimulation System (OMNS) innovative non-invasive therapy is designed to treat the ocular surface and tear film, for long-lasting relief of Dry Eye Disease signs & symptoms.
EpiTech’s proprietary technology is based on neurostimulation by targeted magnetic fields, resulting in the reinforcement of the structural integrity of the ocular surface. The procedure is well-tolerated, non-invasive, and takes just about 10 minutes per eye.
The Viveye OMNS demonstrated safety and effectiveness in clinical studies, providing significant improvement for moderate – severe Dry Eye Disease patients. The Viveye Ocular Magnetic Neurostimulation System is designed for comfortable and ergonomic positioning for the treated subject.
EpiTech is currently enrolling severe dry eye disease patients for our second multicenter clinical study to further validate the safety and effectiveness of the Viveye OMNS.
The company has a solid intellectual property portfolio in the field of ocular neurostimulation and is led by a seasoned team of tech and clinical veterans, with leading KOLs in advisory roles.
Study Results Show Signs and Symptoms Improvement Over Time.
Previous Clinical Study Results
- Safety: Statistical analysis show significant improvement of several factors related to dry eye disease while no clinically significant effects on safety parameters have been observed.
- Corneal staining results for 29 patients show a significant reduction during the course of the study with a statistically significant decrease (improvement) after one week (P=0.002) and a continual clinical meaningful reduction observed on the following visits up to 12 weeks post treatment.
- Symptoms: Quality of life Dry Eye Disease questionnaires results show statistically significant differences from day one post treatment (P=0.014) until 12 weeks (p<0.001) from baseline.
- Eye Lubricant Usage: statistically significant reduction in the use of eye lubricants were observed at 4 weeks post treatment with an increasing reduction in the use of eye lubricants over time until 12 weeks.
4 Weeks Post Treatment
8 Weeks Post Treatment
Efficiently Relieving Dry Eye Symptoms
dry eye relief
Easy to comply
Expanding Treatment Opportunities
Can be administered regardless
of the cause of Dry Eye Disease, expanding treatable patient populations
In-office treatment performed by technicians
EpiTech Mag Ltd. was incorporated in Israel in Feb. 2015 out of the offices of the TerraLab Ventures Incubator